PRQR · NASDAQ
ProQR Therapeutics (PRQR) Stock Price & Fundamentals
ProQR Therapeutics (PRQR) closed at $493.52 on Oct 9, 2026, down 1.52% from the previous close of $501.12.
Share price, past year
1Y −11.85%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $493.52 |
| Sep 30, 2026 | $506.09 |
| Aug 31, 2026 | $522.68 |
| Jul 31, 2026 | $525.41 |
| Jun 30, 2026 | $531.08 |
| May 29, 2026 | $542.79 |
| Apr 30, 2026 | $523.91 |
| Mar 31, 2026 | $533.39 |
| Feb 27, 2026 | $524.33 |
| Jan 30, 2026 | $535.80 |
| Dec 31, 2025 | $559.12 |
| Nov 28, 2025 | $570.68 |
| Oct 31, 2025 | $561.43 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- −€0.40
- Revenue (TTM)
- €15.91M
- Net income (TTM)
- −€42.18M
- Shares outstanding
- 105.4M
- Dividend yield
- —
- 52-week range
- $493.52 – $578.47
Market cap, P/E and dividend yield aren't shown for ProQR Therapeutics yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in euros.
Financials
ProQR Therapeutics reported revenue of €15.91M for fiscal 2025, down 15.86% from fiscal 2024.
Figures are in euros (EUR), as ProQR Therapeutics reports them to the SEC.
ProQR Therapeutics reported a net loss of €42.18M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | €15.91M | −15.9% | −€42.18M | −265.2% | −€0.40 | −€53.81M |
| FY2024ended Dec 31, 2024 | €18.91M | +190.2% | −€27.76M | −146.9% | −€0.32 | −€37.81M |
| FY2023ended Dec 31, 2023 | €6.51M | +81.3% | −€28.12M | −431.7% | −€0.35 | €20.18M |
| FY2022ended Dec 31, 2022 | €3.59M | +169.2% | −€64.42M | −1,792.5% | −€0.90 | −€69.22M |
| FY2021ended Dec 31, 2021 | €1.34M | — | −€60.74M | −4,549.8% | −€0.95 | −€26.50M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | €4.69M | −€8.92M | −€0.08 |
| Q3 FY2025ended Sep 30, 2025 | €2.88M | −€11.01M | −€0.10 |
| Q2 FY2025ended Jun 30, 2025 | €3.82M | −€12.18M | −€0.12 |
| Q1 FY2025ended Mar 31, 2025 | €4.52M | −€10.08M | −€0.10 |
| Q4 FY2024ended Dec 31, 2024 | €4.31M | −€9.31M | −€0.10 |
| Q3 FY2024ended Sep 30, 2024 | €3.84M | −€8.11M | −€0.10 |
| Q2 FY2024ended Jun 30, 2024 | €6.31M | −€2.69M | −€0.03 |
| Q1 FY2024ended Mar 31, 2024 | €4.45M | −€7.66M | −€0.09 |
Company profile
- Name
- ProQR Therapeutics N.V.
- Ticker
- PRQR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Zernikedreef 9, Leiden
- Incorporated in
- P7
- Fiscal year ends
- December
- SEC CIK
- 0001612940
Recent SEC filings
- Mar 12, 2026
- Mar 13, 2025
- Mar 13, 2024
- Mar 29, 2023
- Apr 29, 2022
- Mar 24, 2021
- Mar 31, 2020
- Mar 28, 2019
Frequently asked questions
What is ProQR Therapeutics's stock price?
ProQR Therapeutics (PRQR) closed at $493.52 on Oct 9, 2026, down 1.52% from the previous close of $501.12.
How much revenue does ProQR Therapeutics make?
ProQR Therapeutics reported revenue of €15.91M for fiscal 2025, down 15.86% from fiscal 2024.
Does ProQR Therapeutics pay a dividend?
ProQR Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ProQR Therapeutics N.V.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures